TL;DR
Get sports gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It recommends assessing function, nutrition and cognition before treatment and considering muscle loss, frailty, dehydration and team-based support.
The American Geriatrics Society (AGS) has released a clinical framework for prescribing obesity medications to older adults, including drugs that act through gut-derived hormonal pathways. Published in the Journal of the American Geriatrics Society, the case-based guidance asks clinicians to weigh potential benefits against age-related concerns such as frailty, muscle loss, malnutrition and dehydration.
Developed by the AGS Healthy Aging Special Interest Group, the paper applies the society’s Geriatrics 5Ms Framework to incretin therapy. Its five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. The framework uses clinical cases to help practitioners consider how treatment decisions fit an older person’s health, function and priorities.
The authors recommend assessing functional status, nutritional adequacy and cognitive impairment before starting medication. They also emphasize that weight management should not be considered apart from the possibility of losing lean muscle. Older adults may face particular risks related to sarcopenia and frailty, as well as inadequate nutrition or dehydration, the paper says.
The report describes obesity medications as offering potential benefits for weight management and glycemic control, among other health conditions. It recommends pairing treatment with measures such as resistance training and adequate dietary protein. Depending on the patient’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Balancing Weight Loss With Function
The framework focuses attention on outcomes beyond a change in body weight. For an older patient, preserving mobility, muscle and independence may be part of deciding whether a medication is appropriate and how treatment should be supported. The guidance frames prescribing as an individualized decision, rather than a medication choice made without reference to overall health.
That approach may matter as clinicians consider obesity drugs for a group that has been underrepresented in clinical trials, according to the report. The framework does not establish that these medicines are unsafe or ineffective in older adults. Instead, it identifies age-related factors that practitioners should assess and monitor, while acknowledging the need to weigh possible benefits against risks for each patient.
Its practical emphasis is on connecting prescribing with nutrition, physical activity and the patient’s broader circumstances. A team-based approach can bring in professionals with relevant expertise when one clinician cannot address every issue. The paper presents those supports as considerations for care, not as a guarantee that treatment will prevent muscle loss or other complications.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Solo Stove Bonfire 2.0 Smokeless Wood-Burning Fire Pit with Stand, Silver
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The 5Ms framework is a way to organize care around older adults’ needs. In this paper, Mind and Mobility direct attention to cognition and physical function; Medications and Multicomplexity place treatment within a person’s wider health picture; and Matters Most brings the patient’s priorities into the decision.
The new paper, by Elias M. Wisdom and co-authors, applies that structure to obesity medications, including incretin therapies. It was published in the Journal of the American Geriatrics Society in 2026. The report describes a framework organized around cases, rather than a new drug approval or a clinical trial showing that a particular treatment works in older adults.
The distinction matters: the paper offers a prescribing approach to guide clinical judgment. Its recommendations focus on evaluation before treatment and supportive measures alongside it. The source report does not identify a single medication, dose or monitoring schedule as suitable for every older adult.
“The framework offers a practical approach to prescribing obesity medications to older adults.”
— The report’s description of the AGS paper
Evidence Gaps in Older Patients
The source report does not provide trial results measuring the benefits or harms of these medications specifically in older adults, nor does it quantify how often issues such as lean muscle loss, malnutrition or dehydration occur. It also does not report patient outcomes from applying the framework in clinical practice.
The paper’s case-based guidance does not establish that every older adult should receive an obesity medication, or specify a universal threshold for treatment. Which medication, if any, fits a particular patient remains a clinical decision. The degree to which the recommended co-interventions change outcomes is not stated in the source material.
Further details about the cases, the framework’s implementation and any subsequent evaluation are not provided in the report. The available information supports describing this as a clinical decision-making framework, not proof that a particular prescribing strategy is safer or more effective.
How Clinicians May Apply It
The paper is now available in the Journal of the American Geriatrics Society for clinicians to consult. In practice, its approach points to an assessment before prescribing that covers function, nutrition and cognition, followed by consideration of exercise and dietary support alongside medication where appropriate.
The source report gives no timetable for further AGS guidance, implementation studies or clinical trials in older adults. The next evidence needed would include research that directly examines outcomes in this population, including how treatment affects mobility, lean mass and nutritional health. Until then, the paper’s recommendations should be understood as a structured aid to individualized care, with important questions about outcomes still open.
Key Questions
What did the American Geriatrics Society release?
The AGS released a case-based framework to guide clinicians considering obesity medications for older adults. It applies the Geriatrics 5Ms to prescribing decisions.
Which concerns does the framework highlight?
It calls attention to frailty, sarcopenia, lean muscle loss, malnutrition and dehydration, alongside assessment of function, nutrition and cognition before treatment.
Does the framework recommend medication for every older adult with obesity?
No. The report describes a tool for individualized clinical decisions; it does not say that all older adults should receive these medications or name one treatment as appropriate for everyone.
What should accompany medication, according to the paper?
The authors recommend considering resistance training and adequate dietary protein. Some patients may benefit from support by a dietitian, physical therapist, fitness trainer or behavioral health professional.
What remains unknown?
The report does not provide quantified outcomes showing how the framework affects patients or establish the benefits and risks of specific obesity medicines in older adults. More evidence in this population is needed.
Source: medicalxpress.com
